0001062993-24-012734.txt : 20240617 0001062993-24-012734.hdr.sgml : 20240617 20240617203839 ACCESSION NUMBER: 0001062993-24-012734 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240617 FILED AS OF DATE: 20240617 DATE AS OF CHANGE: 20240617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kieffer Tara Lynn CENTRAL INDEX KEY: 0001834835 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 241049921 MAIL ADDRESS: STREET 1: C/O ENANTA PHARMACEUTICALS, INC. STREET 2: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-06-17 0001177648 ENANTA PHARMACEUTICALS INC ENTA 0001834835 Kieffer Tara Lynn C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 0 1 0 0 Chief Product Strategy Officer 1 Common Stock 2024-06-17 4 S 0 7266 12.33 D 32341 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.54, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 above. /s/ Paul J. Mellett as attorney-in-fact 2024-06-17